Effects of uremia and inflammation on growth hormone resistance in patients with chronic kidney diseases

Kidney International

Volumn 74, Issue 7, 2008, Pages 937-945

  Garibotto, Giacomo ^a,b,f   Russo, Rodolfo ^a,b   Sofia, Antonella ^a,b   Ferone, Diego ^b,c   Fiorini, Fulvio ^d   Cappelli, Valeria ^a,b   Tarroni, Alice ^a,b   Gandolfo, Maria Teresa ^a   Vigo, Emanuela ^a,b   Valli, Alessandro ^a   Arvigo, Marica ^c   Verzola, Daniela ^a   Ravera, Giovanbattista ^e   Minuto, Francesco ^b,c  

^a Department of Internal Medicine   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c DiSEM   (Italy)

^d Ospedale di Sanremo   (Italy)

^e Department of Health Sciences Biostatistics Section ^*  (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Amino acid; Chronic renal failure; Growth hormone; Inflammation; K+; Malnutrition

Indexed keywords

BRANCHED CHAIN AMINO ACID; C REACTIVE PROTEIN; HORMONE RECEPTOR; HUMAN GROWTH HORMONE; INTERLEUKIN 6; POTASSIUM;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; INFLAMMATION; MALE; POTASSIUM BALANCE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; UREMIA;

EID: 51849106367     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2008.345     Document Type: Article

References (49)

1. Mitch WE. Proteolytic mechanisms, not malnutrition, cause loss of muscle mass in kidney failure. J Ren Nutr 2006; 16: 208-211.
2. Bergstrom J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of view. Am J Kidney Dis 1998; 32: 834-841.
3. Kalantar-Zadeh K, Kopple JD, Block G et al. A malnutrition- inflammation score is correlated with morbidity and mortality in maintenance hemodialysis patients. Am J Kidney Dis 2001; 38: 1251-1263.
4. Kopple JD, Greene T, Chumlea WC et al. Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD study. Kidney Int 2000; 57: 1688-1703.
5. Mitch WE. Uremic acidosis and protein metabolism. Curr Opin Nephrol Hypertens 1995; 4: 488-492.
6. Fryburg DA, Louard RJ, Gerow KE. Growth hormone stimulates skeletal muscle protein synthesis and antagonizes insulin's antiproteolytic action in humans. Diabetes 1992; 41: 424-429.
7. Umpleby AM, Russell-Jones DL. The hormonal control of protein metabolism. Baillieres Clin Endocrinol Metab 1996; 10: 551-570.
8. Kaskel F. Chronic renal disease: a growing problem. Kidney Int 2003; 64: 1141-1151.
9. Chen Y, Fervenza FC, Rabkin R. Growth factors in the treatment of wasting in kidney failure. J Ren Nutr 2001; 11: 62-66.
10. Qing Peiyuan D, Ding HU, Vadgama J et al. Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1-stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 1999; 10: 84-92.
11. Powell DR, Zhao D, Durham SK et al. Decreased hepatic insulin-like growth factor (IGF)-I and increased IGF binding protein-1 and -2 gene expression in experimental uremia. Endocrinology 1997; 138: 938-946.
12. Blum WF, Ranke MB, Kietzmann K et al. Growth hormone resistance and inhibition of somatomedin activity by excess of insulin-like growth factor binding protein in uremia. Pediatr Nephrol 1991; 5: 539-544.
13. Sun DF, Zheng Z, Tummala P et al. Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle. J Am Soc Nephrol 2004; 15: 2630-2646.
14. Fouque D, Peng SC, Kopple JD. Impaired metabolic response to recombinant insulin-like growth factor-1 in dialysis patients. Kidney Int 1995; 47: 876-883.
15. Fouque D, Peng SC, Shamir E et al. Recombinant human insulin-like growth factor-1 induces an anabolic response in malnourished CAPD patients. Kidney Int 2000; 57: 646-654.
16. Ikizler TA, Wingard RL, Flakoll PJ et al. Effects of recombinant human growth hormone on plasma and dialysate amino acid profiles in CAPD patients. Kidney Int 1996; 50: 229-234.
17. Garibotto G, Barreca A, Russo R et al. Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest 1997; 99: 97-105.
18. Pupim LB, Flakoll PJ, Yu C et al. Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr 20055; 82: 1235-1243.
19. Kotzmann H, Yilmaz N, Lercher P et al. Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int 2001; 60: 1578-1585.
20. Kopple JD, Brunori G, Leiserowitz M et al. Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant 2005; 20: 952-958.
21. Feldt-Rasmussen B, Lange M, Sulowicz W et al. Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol 2007; 18: 2161-2171.
22. Cuneo RC, Salomon F, Wiles CM et al. Growth hormone treatment in growth hormone-deficient adults. I. Effects on muscle mass and strength. J Appl Physiol 1991; 70: 688-694.
23. Cooney RN, Shumate M. The inhibitory effects of interleukin-1 on growth hormone action during catabolic illness. Vitam Horm 2006; 74: 317-340.
24. Brungger M, Hulter HN, Krapf R. Effect of chronic metabolic acidosis on the growth hormone/IGF-1 endocrine axis: new cause of growth hormone insensitivity in humans. Kidney Int 1997; 51: 216-221.
25. Robinson IC, Gevers E. Visualizing and manipulating growth hormone (GH) responses in muscle and other GH target tissues. Horm Res 2006; 66S1: 35-41.
26. Ljungberg A, Linden D, Ameen C et al. Importance of PPAR alpha for the effects of growth hormone on hepatic lipid and lipoprotein metabolism. Growth Horm IGF Res 2007; 17: 154-164.
27. Hayashi AA, Proud CG. The rapid activation of protein synthesis by growth hormone requires signaling through the mammalian target of rapamycin, mTOR. Am J Physiol Endocrinol Metab 2007; 292: E1647-E1655.
28. Salomon F, Cuneo RC, Hesp R et al. Basal metabolic rate in adults with growth hormone deficiency and in patients with acromegaly: relationship with lean body mass, plasma insulin level and leucocyte sodium pump activity. Clin Sci 1992; 83: 325-330.
29. Olivecrona H, Hilding A, Ekstrom C et al. Acute and short-term effects of growth hormone on insulin-like growth factors and their binding proteins: serum levels and hepatic messenger ribonucleic acid responses in humans. J Clin Endocrinol Metab 1999; 84: 553-560.
30. Fryburg D, Gelfand G. Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism 1993; 42: 1223-1227.
31. Haddad F, Zaldivar F, Cooper DM et al. IL-6-induced skeletal muscle atrophy. J Appl Physiol 2005; 98: 911-917.
32. Widmer B, Gerhardt RE, Harrington JT et al. Serum electrolyte and acid base composition. The influence of graded degrees of chronic renal failure. Arch Intern Med 1979; 139: 1099-1102.
33. Gennari FJ, Segal AS. Hyperkalemia: an adaptive response in chronic renal insufficiency. Kidney Int 2002; 62: 1-9.
34. Allon M, Copckney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney Int 1990; 38: 869-872.
35. Vahl N, Moller N, Lauritzen T et al. Metabolic effects and pharmacokinetics of a growth hormone pulse in healthy adults: relation to age, sex, and body composition. J Clin Endocrinol Metab 1997; 82: 3612-3618.
36. Hansen TK, Gravholt CH, ØRskov H et al. Dose dependency of the pharmacokinetics and acute lipolytic actions of growth hormone. J Clin Endocrinol Metab 2002; 87: 4691-4698.
37. Baumann G, Amburn K, Shaw MA. The circulating growth hormone (GH)-binding protein complex: a major constituent of plasma GH in man. Endocrinology 1988; 122: 976-984.
38. Greenstein J, Guest S, Tan JC et al. Circulating growth hormone binding protein levels and mononuclear cell growth hormone receptor expression in uremia. J Ren Nutr 2006; 16: 141-149.
39. Nathan J, Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord 2006; 7: 225-235.
40. Chen Y, Sun D, Krishnamurthy VM et al. Endotoxin attenuates growth hormone induced hepatic insulin-like growth factor-1 expresion by inhibiting Jak2/Stat5 signal transduction and Stat5b DNA binding. Am J Physiol Endocrinol Metab 2007; 292: E1856-E1862.
41. Honda H, Qureshi AR, Heimburger O et al. Serum albumin, C-reactive protein, interleukin-6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 2006; 47: 139-148.
42. Toth MJ, Matthews DE, Tracy RP et al. Age-related differences in skeletal muscle protein synthesis: relation to markers of immune activation. Am J Physiol Endocrinol Metab 2005; 288: E883-E891.
43. Lang CH, Frost RA, Nairn AC et al. TNF-a impairs heart and skeletal muscle protein synthesis by altering translation initiation. Am J Physiol Endocrinol Metab 2002; 282: E336-E347.
44. Greiwe JS, Cheng B, Rubin DC et al. Resistance exercise decreases skeletal muscle tumor necrosis factor in frail elderly humans. FASEB J 2001; 15: 475-482.
45. Garibotto G, Sofia A, Procopio V et al. Peripheral tissue release of Interleukin-6 in patients with chronic kidney diseases: effects of end-stage renal disease and microinflammatory state. Kidney Int 2006; 70: 384-390.
46. Forster HV, Dempsey JA, Thomson J et al. Estimation of arterial PO2, PCO2, pH and lactate from arterialized venous blood. J Appl Physiol 1971; 32: 134-137.
47. Strasburger CJ. Laboratory assessment of GH. Growth Horm IGF Res 1998; 8: S41-S46.
48. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
49. Heymsfield SB, Mc Manus C, Smith J et al. Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr 1982; 36: 680-690.